We have compiled a list of manufacturers, distributors, product information, reference prices, and rankings for medicine.
ipros is IPROS GMS IPROS One of the largest technical database sites in Japan that collects information on.

medicine Product List and Ranking from 33 Manufacturers, Suppliers and Companies

Last Updated: Aggregation Period:Oct 01, 2025~Oct 28, 2025
This ranking is based on the number of page views on our site.

medicine Manufacturer, Suppliers and Company Rankings

Last Updated: Aggregation Period:Oct 01, 2025~Oct 28, 2025
This ranking is based on the number of page views on our site.

  1. マーケットリサーチセンター Tokyo//Service Industry
  2. キアゲン Tokyo//others
  3. スペラファーマ Osaka//others
  4. 4 null/null
  5. 5 関東化学株式会社 バイオケミカル部 Tokyo//Chemical

medicine Product ranking

Last Updated: Aggregation Period:Oct 01, 2025~Oct 28, 2025
This ranking is based on the number of page views on our site.

  1. Digital PCR kit (reaction reagents) キアゲン
  2. Contract development and manufacturing (CDMO) business for mid-sized molecules (oligonucleotides and peptides) active pharmaceutical ingredients.
  3. For various titrations! The titration "indicator" specified in JIS K8001. 関東化学株式会社 バイオケミカル部
  4. Tateyama Kasei Co., Ltd. Kyushu Factory 立山化成
  5. 4 Cavity prevention medicine Gurupepr カツマタ 医薬品製造販売部

medicine Product List

286~300 item / All 548 items

Displayed results

[Research Material] The Global Market for Alzheimer's Disease Treatments

World Market for Alzheimer's Disease Treatments: Donepezil, Memantine, Rivastigmine, Early to Moderate Stage, Moderate to Severe Stage

This research report (Global Alzheimer’s Therapeutics Market) investigates and analyzes the current state and outlook for the global market for Alzheimer’s disease treatments over the next five years. It includes information on the overview of the global Alzheimer’s disease treatment market, trends of major companies (sales, selling prices, market share), market size by segment, market size by major regions, and distribution channel analysis. The market segments by type include Donepezil, Memantine, and Rivastigmine, while the segments by application focus on early to moderate stages and moderate to severe stages. The regional segments are divided into North America, the United States, Europe, Asia-Pacific, Japan, China, India, South Korea, Southeast Asia, South America, the Middle East, and Africa, to calculate the market size for Alzheimer’s disease treatments. It also includes the market share of major companies in Alzheimer’s disease treatments, product and business overviews, and sales performance.

  • Other services

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Global Market for Stroke Prevention in Atrial Fibrillation (SPAF) Treatment

Global Market for Stroke Prevention in Atrial Fibrillation (SPAF) Treatment: Oral Direct Thrombin Inhibitors, Oral Direct Factor Xa Inhibitors, Hospitals, Clinics ...

This research report (Global Stroke Prevention in Atrial Fibrillation (SPAF)) investigates and analyzes the current state and future outlook of the global market for stroke prevention in the treatment of atrial fibrillation (SPAF) over the next five years. It includes information on the overview of the global stroke prevention market in atrial fibrillation (SPAF) treatment, trends of major companies (sales, selling prices, market share), market size by segment, market size by major regions, and distribution channel analysis. The market segments for stroke prevention in atrial fibrillation (SPAF) treatment by type focus on oral direct thrombin inhibitors and oral direct factor Xa inhibitors, while the segments by application target hospitals, clinics, and outpatient surgical centers. The regional segments are divided into North America, the United States, Europe, Asia-Pacific, Japan, China, India, South Korea, Southeast Asia, South America, the Middle East, and Africa, to calculate the market size for stroke prevention in atrial fibrillation (SPAF) treatment. It also includes the market share of major companies in stroke prevention for atrial fibrillation (SPAF) treatment, product and business overviews, and sales performance.

  • Other services

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

[Market Report] Global Market for Point-of-Care Diagnostic Tests

With the rapid increase in demand for swift and accurate testing, the global market for POC (point-of-care) diagnostic tests is experiencing rapid growth.

The global POC market is experiencing unprecedented growth due to the increasing demand for rapid and accurate testing solutions. Point-of-care diagnostic tests, also known as bedside testing or near-patient testing, enable timely decision-making by healthcare professionals and improve patient outcomes through rapid diagnosis and treatment. As the value of rapid and accurate testing is recognized by healthcare institutions worldwide in enhancing patient care and streamlining healthcare delivery, the global POC market is poised for continued growth. Please check the application method from the [PDF download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

[Market Report] Global Market for Agricultural Bio Products

The global agricultural biologicals market is expected to expand and reach 43.6 billion USD by 2031.

The global market for agricultural biological products has achieved remarkable growth, with estimated sales reaching $12.4 billion in 2022. This promising upward trend is expected to continue, with projections indicating an astonishing market size of $43.6 billion by 2031. The industry is anticipated to experience significant growth, with a compound annual growth rate (CAGR) of 15% during the forecast period from 2023 to 2031. Agricultural biological products, including biopesticides, biofertilizers, and biostimulants, have gained tremendous support in recent years. They are welcomed as sustainable alternatives to traditional chemical-based agricultural products, aligning with the global rise in emphasis on environmentally friendly and organic farming practices. For application methods, please check the [PDF download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

[Market Report] Global Market for Neuropathic Pain Medications

The global market for neuropathic pain treatment drugs is expected to rapidly expand to $10.4 billion by 2031, alleviating suffering worldwide.

The global market for neuropathic pain medications is specialized in improving the lives of people suffering from neuropathic pain and has made significant progress. In 2022, this important market generated approximately $5.8 billion in revenue. It is projected to reach an estimated $10.4 billion by 2031, showing a stable compound annual growth rate (CAGR) of 5% during the forecast period from 2023 to 2031. Neuropathic pain is characterized by sharp, stabbing pain and burning sensations, often caused by nerve damage or dysfunction. Neuropathic pain is a complex condition that significantly impacts the quality of life for millions of people worldwide. You can check the application method by clicking the [PDF Download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

[Market Report] Global Market for Psoriasis Treatments

The global market for psoriasis treatments is expected to rapidly expand, reaching 55.72 billion USD by 2031.

The global market for psoriasis treatments has experienced significant growth and plays a crucial role in addressing this challenging skin condition. In 2022, the market size reached 25.2 billion USD and is projected to reach 55.72 billion USD by 2031. This notable increase indicates a steady compound annual growth rate (CAGR) of 9.3% during the forecast period from 2023 to 2031. Psoriasis is a chronic skin disease affecting millions of people worldwide, characterized by red, itchy, scaly patches on the skin's surface. The increasing prevalence of psoriasis, heightened awareness, and advancements in treatment options are driving the expansion of the psoriasis treatment market. For application methods, please check the [PDF download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

[Market Report] Global Market for Pulmonary Arterial Hypertension

The global market for pulmonary arterial hypertension is projected to reach 10.8 billion dollars by 2031.

The global pulmonary arterial hypertension (PAH) market reached a revenue of $7 billion in 2022 and is aiming for significant growth. Projections indicate that the market will reach $10.8 billion by 2031, with a compound annual growth rate (CAGR) of 5% from 2023 to 2031. This growth reflects the increasing demand for effective treatments for this serious and life-threatening disease. Pulmonary arterial hypertension is a rare but severe condition characterized by high blood pressure in the lungs. It involves narrowing or blockage of the pulmonary arteries and capillaries, leading to increased strain on the heart and gradually worsening symptoms. Without timely and effective treatment, PAH can be life-threatening, highlighting the urgent need for advanced treatment options. For application methods, please check the [PDF download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

[Market Report] Global Diabetic Nephropathy Market

The global diabetic nephropathy market is advancing in the fight against kidney disease, expected to reach 3.37 billion USD by 2031.

The global diabetic nephropathy market is at the forefront of combating kidney disorders in diabetic patients, offering hope and advanced treatment options. According to recent market reports, the global diabetic nephropathy market generated approximately $2 billion in revenue in 2022 and is estimated to surge to about $3.37 billion by 2031. This noteworthy growth trajectory is driven by a solid annual compound growth rate (CAGR) of 6% projected from 2023 to 2031. Diabetic nephropathy, a long-term kidney disorder, is a significant concern for those living with diabetes. This condition occurs when persistently elevated blood sugar levels cause damage to kidney function. Diabetic nephropathy can affect patients with type 2 diabetes and is primarily characterized by damage to the smallest blood vessels in the kidneys. When these small blood vessels are damaged, proteins begin to leak into the urine from both kidneys, indicating renal dysfunction. You can check the application method by clicking the [PDF Download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

[Market Report] Global Nucleic Acid Medicine Market

Global Nucleic Acid Drug Market: Expected to Reach 12 Billion USD by 2031 Due to Advances in Precision Medicine and Targeted Therapies.

The global nucleic acid therapeutics market is at the forefront of the pharmaceutical industry's push towards precision medicine and targeted therapies. According to recent market reports, the global nucleic acid therapeutics market is estimated to achieve approximately $4.5 billion in revenue by 2022 and surge to $12 billion by 2031. This remarkable growth trajectory is driven by powerful compounds. The compound annual growth rate (CAGR) is projected to be 11.6% from 2023 to 2031. Nucleic acid therapeutics encompass a wide range of innovative treatments, including ribonucleic acid (RNA) therapeutics and deoxyribonucleic acid (DNA) therapeutics. These therapies further include enzymes, antisense oligonucleotides, DNA aptamers, ribozymes, micro RNA, RNA decoys, and short interfering RNA, all designed to target disease-causing genes while preserving healthy cells and tissues. For application methods, please check the [PDF download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

[Market Report] Global Lyme Disease Treatment Market

The global Lyme disease treatment market is expected to achieve steady growth, reaching 1.652 billion USD by 2031.

The global Lyme disease treatment market is aiming for significant expansion, with revenues reaching approximately $799.4 million in 2022. Recent market analysis indicates that this sector is expected to experience a robust compound annual growth rate (CAGR) of 8.4% in 2022. The forecast period is from 2023 to 2031, with an estimated value of $1.652 billion by 2031. This increase is attributed to the rising global prevalence of Lyme disease and the development of innovative treatments. As the prevalence of Lyme disease continues to rise and research efforts focus on developing more effective treatment options, the global Lyme disease treatment market is poised for continuous growth. Increased investment in research and development, expanded access to healthcare, and heightened awareness of Lyme disease among healthcare professionals and the general public are expected to lead to significant advancements in the diagnosis and treatment of this debilitating disease. For application methods, please check the [PDF download] button or apply directly through the related links.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Current Status of Pain Treatment: Medical Needs, Basic Research, and Exploration of New Therapeutics

★What are the actual drug selection and treatment processes for chronic pain management? ★Profile of the desired medication, expected cascade, and promising future analgesic cascades.

【Lecturers】 Professor Shinsuke Hamaguchi, Department of Anesthesiology, Dokkyo Medical University Dr. Kenji Miki, Deputy Chief of Orthopedics, Amagasaki Central Hospital, Specialist in Pain Management, Osaka University Medical Hospital 【Venue】Industrial Promotion Hall, Conference Room 1【Kanagawa, Kawasaki Station】 【Date and Time】December 13, 2010 (Monday) 11:00-15:00 【Capacity】30 people *Registration will close once full. Please apply early. 【Participation Fee】45,150 yen per person (including tax, textbook fee, and tea cost) New members applying for the first time by December 3 will receive an early bird discount price of 39,900 yen. ◆For two applicants from the same organization, the fee is 69,300 yen. For more details or to consider applying, please use the URL below ▼ http://ec.techzone.jp/products/detail.php?product_id=1270

  • Company:AndTech
  • Price:10,000 yen-100,000 yen
  • Technical Seminar

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Key Points of Global Quality Assurance System and Safety Assurance in GMP for Investigational Drugs

★A thorough explanation from the basics to global compliance measures for clinical trial drug GMP, taking into account audit experience! ★Introducing many actual concrete examples, including responses to QP!

【Instructor】QA Advisor, Doctor of Medicine, Akira Nomura 【Venue】Kawasaki City Educational and Cultural Center, Room 1  【Kanagawa, Kawasaki】10 minutes on foot from JR and Keikyu "Kawasaki Station," 12 minutes from JR Shinagawa Station to Kawasaki Station 【Date and Time】January 26, 2011 (Wednesday) 13:00-16:30 【Capacity】30 people 【Attendance Fee】45,150 yen per person (including tax and text costs)

  • Company:AndTech
  • Price:10,000 yen-100,000 yen
  • Technical Seminar

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tateyama Chemical Co., Ltd. Quality Assurance System

With "creative practice" as a keyword, we are constantly reevaluating our quality assurance system.

Our company started with the production of methyl ephedrine, an active pharmaceutical ingredient (API) for expectorants. The manufacturing of APIs and their quality control are the very roots of Tateyama Chemical. Aiming for world-class quality assurance, we achieve global-level quality assurance that complies not only with Japan's GMP, which is the standard for pharmaceutical manufacturing and quality control, but also with PIC/S GMP, to supply safe, effective, and high-quality pharmaceuticals to countries around the world. To respond to the trust of various customers and ultimately the end users, we will continuously update our quality control system. 【Management Policy】 ■ Development of new products ■ Refinement of technology ■ Thorough implementation of 5S and quality control ■ Raising awareness of environmental conservation and health and safety *For more details, please refer to the PDF materials or feel free to contact us.

  • Contract manufacturing
  • Chemicals

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Aptamer drug discovery technology

Created using the SELEX method (in vitro artificial evolution method)! It is possible to develop various new drugs.

We would like to introduce our "Aptamer Drug Discovery Technology." Our core drug discovery technology, the "RiboART System," is built on comprehensive technologies, knowledge, and experience related to aptamer drug discovery, creating a platform (drug discovery foundation) that can be widely applied to the generation of new drug candidates. By using this system, it is possible to create various new drugs that are not limited to specific diseases or target proteins. 【Flow】 ■ SELEX method ■ Binding property measurement ■ Shortening, re-SELEX, chemical modification ■ Cell testing ■ Animal testing ■ Toxicity testing *For more details, please refer to the PDF document or feel free to contact us.

  • Other Protein Research

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

[CPhI Seminar Report] Mutagenic Impurities in Pharmaceuticals (Active Pharmaceutical Ingredients)

Development of testing methods and analysis examples! Established over 300 analytical methods that can guarantee PMI residues below 10 ppm!

At "CPhI Japan 2022," we held a presentation in our booth regarding ICH M7 compliance from the Development and Analytical Research Headquarters. We introduced the day's content, including "About ICH M7," "For the Development of Trace Analysis Methods," and "Examples of Method Validation." Please take a moment to read it. [Contents] ■ About ICH M7 ■ For the Development of Trace Analysis Methods ■ Examples of Method Validation ■ Conclusion *For more details, please refer to the related links page or feel free to contact us.

  • Other Testing Contract

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Search Keywords Related to medicine